<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33823304</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1525-0024</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month><Day>05</Day></PubDate></JournalIssue><Title>Molecular therapy : the journal of the American Society of Gene Therapy</Title><ISOAbbreviation>Mol Ther</ISOAbbreviation></Journal><ArticleTitle>Novel genome-editing-based approaches to treat motor neuron diseases: Promises and challenges.</ArticleTitle><Pagination><StartPage>47</StartPage><EndPage>53</EndPage><MedlinePgn>47-53</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ymthe.2021.04.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1525-0016(21)00190-8</ELocationID><Abstract><AbstractText>Motor neuron diseases are untreatable with common pharmacological approaches. Spinal muscular atrophy (SMA) is caused by SMN1 gene mutations leading to lowered SMN expression. Symptoms are alleviated in infants with a higher copy number of the SMN2 gene, which, however, displays a splicing defect resulting in low SMN levels. Amyotrophic lateral sclerosis (ALS) is caused by a number of mutations, with C9orf72 repeat expansions the most common genetic cause and SOD1 gain-of-function mutations the first genetic cause identified for this disease. Genetic therapies based on oligonucleotides that enhance SMN2 splicing and SMN production or lower SOD1 expression have shown promise in initial clinical trials for individuals with SMA and ALS harboring SOD1 mutations, respectively. Gene addition/silencing approaches using adeno-associated viruses (AAVs) are also currently under clinical investigation in trials for SMA and ALS. Here we provide a brief overview of these efforts and their advantages and challenges. We also review genome editing approaches aimed at correcting the disease-causing mutations or modulating the expression of genetic modifiers, e.g., by repairing SOD1 mutations or the SMN2 splicing defect or deleting C9orf72 expanded repeats. These studies have shown promising results to approach therapeutic trials that should significantly lower the progression of these deadly disorders.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miccio</LastName><ForeName>Annarita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Chromatin and Gene Regulation during Development, Imagine Institute, Universit&#xe9; de Paris, INSERM UMR 1163, 75015, Paris, France. Electronic address: annarita.miccio@institutimagine.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antoniou</LastName><ForeName>Panagiotis</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Laboratory of Chromatin and Gene Regulation during Development, Imagine Institute, Universit&#xe9; de Paris, INSERM UMR 1163, 75015, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciura</LastName><ForeName>Sorana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory of Translational Research for Neurological Disorders, Imagine Institute, Universit&#xe9; de Paris, INSERM UMR 1163, 75015, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kabashi</LastName><ForeName>Edor</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Laboratory of Translational Research for Neurological Disorders, Imagine Institute, Universit&#xe9; de Paris, INSERM UMR 1163, 75015, Paris, France. Electronic address: edor.kabashi@institutimagine.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Ther</MedlineTA><NlmUniqueID>100890581</NlmUniqueID><ISSNLinking>1525-0016</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009841">Oligonucleotides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D055533">Survival of Motor Neuron 1 Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072669" MajorTopicYN="N">Gene Editing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009134" MajorTopicYN="Y">Muscular Atrophy, Spinal</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009841" MajorTopicYN="N">Oligonucleotides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012326" MajorTopicYN="N">RNA Splicing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055533" MajorTopicYN="N">Survival of Motor Neuron 1 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">CRISPR</Keyword><Keyword MajorTopicYN="N">SMA</Keyword><Keyword MajorTopicYN="N">base editing</Keyword><Keyword MajorTopicYN="N">genome editing</Keyword><Keyword MajorTopicYN="N">motor neuron diseases</Keyword></KeywordList><CoiStatement>Declaration of interests The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>6</Day><Hour>20</Hour><Minute>11</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33823304</ArticleId><ArticleId IdType="pmc">PMC8753272</ArticleId><ArticleId IdType="doi">10.1016/j.ymthe.2021.04.003</ArticleId><ArticleId IdType="pii">S1525-0016(21)00190-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Verhaart I.E.C., Robertson A., Wilson I.J., Aartsma-Rus A., Cameron S., Jones C.C., Cook S.F., Lochm&#xfc;ller H. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. Orphanet J. Rare Dis. 2017;12:124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5496354</ArticleId><ArticleId IdType="pubmed">28676062</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirth B. Spinal Muscular Atrophy: In the Challenge Lies a Solution. Trends Neurosci. 2021;44:306&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pubmed">33423791</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J.K., Monani U.R. Augmenting the SMN Protein to Treat Infantile Spinal Muscular Atrophy. Neuron. 2018;97:1001&#x2013;1003.</Citation><ArticleIdList><ArticleId IdType="pubmed">29518354</ArticleId></ArticleIdList></Reference><Reference><Citation>Groen E.J.N., Talbot K., Gillingwater T.H. Advances in therapy for spinal muscular atrophy: promises and challenges. Nat. Rev. Neurol. 2018;14:214&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">29422644</ArticleId></ArticleIdList></Reference><Reference><Citation>Calucho M., Bernal S., Al&#xed;as L., March F., Vencesl&#xe1; A., Rodr&#xed;guez-&#xc1;lvarez F.J., Aller E., Fern&#xe1;ndez R.M., Borrego S., Mill&#xe1;n J.M., et al. Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. Neuromuscul. Disord. 2018;28:208&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">29433793</ArticleId></ArticleIdList></Reference><Reference><Citation>Swoboda K.J., Prior T.W., Scott C.B., McNaught T.P., Wride M.C., Reyna S.P., Bromberg M.B. Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Ann. Neurol. 2005;57:704&#x2013;712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4334582</ArticleId><ArticleId IdType="pubmed">15852397</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthur K.C., Calvo A., Price T.R., Geiger J.T., Chi&#xf2; A., Traynor B.J. Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nat. Commun. 2016;7:12408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4987527</ArticleId><ArticleId IdType="pubmed">27510634</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T., Al Khleifat A., Meurgey J.H., Jones A., Leigh P.N., Bensimon G., Al-Chalabi A. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol. 2018;17:416&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5899963</ArticleId><ArticleId IdType="pubmed">29525492</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen D.R. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;364:362.</Citation><ArticleIdList><ArticleId IdType="pubmed">8332197</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney M.E. The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies. J.&#xa0;Neurol. Sci. 1997;152(Suppl 1):S67&#x2013;S73.</Citation><ArticleIdList><ArticleId IdType="pubmed">9419057</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M., Mackenzie I.R., Boeve B.F., Boxer A.L., Baker M., Rutherford N.J., Nicholson A.M., Finch N.A., Flynn H., Adamson J., et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton A.E., Majounie E., Waite A., Sim&#xf3;n-S&#xe1;nchez J., Rollinson S., Gibbs J.R., Schymick J.C., Laaksovirta H., van Swieten J.C., Myllykangas L., et al. ITALSGEN Consortium A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor J.P., Brown R.H., Jr., Cleveland D.W. Decoding ALS: from genes to mechanism. Nature. 2016;539:197&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciura S., Lattante S., Le Ber I., Latouche M., Tostivint H., Brice A., Kabashi E. Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis. Ann. Neurol. 2013;74:180&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">23720273</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciura S., Sellier C., Campanari M.L., Charlet-Berguerand N., Kabashi E. The most prevalent genetic cause of ALS-FTD, C9orf72 synergizes the toxicity of ATXN2 intermediate polyglutamine repeats through the autophagy pathway. Autophagy. 2016;12:1406&#x2013;1408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4968221</ArticleId><ArticleId IdType="pubmed">27245636</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel R.S., Mercuri E., Darras B.T., Connolly A.M., Kuntz N.L., Kirschner J., Chiriboga C.A., Saito K., Servais L., Tizzano E., et al. ENDEAR Study Group Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N.&#xa0;Engl. J. Med. 2017;377:1723&#x2013;1732.</Citation><ArticleIdList><ArticleId IdType="pubmed">29091570</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vivo D.C., Bertini E., Swoboda K.J., Hwu W.L., Crawford T.O., Finkel R.S., Kirschner J., Kuntz N.L., Parsons J.A., Ryan M.M., et al. NURTURE Study Group Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul. Disord. 2019;29:842&#x2013;856.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7127286</ArticleId><ArticleId IdType="pubmed">31704158</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua Y., Vickers T.A., Okunola H.L., Bennett C.F., Krainer A.R. Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am. J. Hum. Genet. 2008;82:834&#x2013;848.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2427210</ArticleId><ArticleId IdType="pubmed">18371932</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts T.C., Langer R., Wood M.J.A. Advances in oligonucleotide drug delivery. Nat. Rev. Drug Discov. 2020;19:673&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7419031</ArticleId><ArticleId IdType="pubmed">32782413</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhuri K., Bechtold C., Quijano E., Pham H., Gupta A., Vikram A., Bahal R. Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development. J.&#xa0;Clin. Med. 2020;9:2004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7355792</ArticleId><ArticleId IdType="pubmed">32604776</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendell J.R., Al-Zaidy S., Shell R., Arnold W.D., Rodino-Klapac L.R., Prior T.W., Lowes L., Alfano L., Berry K., Church K., et al. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. N.&#xa0;Engl. J. Med. 2017;377:1713&#x2013;1722.</Citation><ArticleIdList><ArticleId IdType="pubmed">29091557</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendell J. Onasemnogene Abeparvovec-xioi (ZOLGENSMA) in SMA 1 Patients. ASGCT Annual Meeting. 2020;406</Citation></Reference><Reference><Citation>Miller T.M., Pestronk A., David W., Rothstein J., Simpson E., Appel S.H., Andres P.L., Mahoney K., Allred P., Alexander K., et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013;12:435&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3712285</ArticleId><ArticleId IdType="pubmed">23541756</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller C., Berry J.D., McKenna-Yasek D.M., Gernoux G., Owegi M.A., Pothier L.M., Douthwright C.L., Gelevski D., Luppino S.D., Blackwood M., et al. SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS. N.&#xa0;Engl. J. Med. 2020;383:151&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">32640133</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappella M., Ciotti C., Cohen-Tannoudji M., Biferi M.G. Gene Therapy for ALS-A Perspective. Int. J. Mol. Sci. 2019;20:4388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6771059</ArticleId><ArticleId IdType="pubmed">31500113</ArticleId></ArticleIdList></Reference><Reference><Citation>Deltcheva E., Chylinski K., Sharma C.M., Gonzales K., Chao Y., Pirzada Z.A., Eckert M.R., Vogel J., Charpentier E. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature. 2011;471:602&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3070239</ArticleId><ArticleId IdType="pubmed">21455174</ArticleId></ArticleIdList></Reference><Reference><Citation>Mali P., Yang L., Esvelt K.M., Aach J., Guell M., DiCarlo J.E., Norville J.E., Church G.M. RNA-guided human genome engineering via Cas9. Science. 2013;339:823&#x2013;826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3712628</ArticleId><ArticleId IdType="pubmed">23287722</ArticleId></ArticleIdList></Reference><Reference><Citation>Cong L., Ran F.A., Cox D., Lin S., Barretto R., Habib N., Hsu P.D., Wu X., Jiang W., Marraffini L.A., Zhang F. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339:819&#x2013;823.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3795411</ArticleId><ArticleId IdType="pubmed">23287718</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang W.Y., Fu Y., Reyon D., Maeder M.L., Tsai S.Q., Sander J.D., Peterson R.T., Yeh J.R., Joung J.K. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat. Biotechnol. 2013;31:227&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3686313</ArticleId><ArticleId IdType="pubmed">23360964</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosicki M., Tomberg K., Bradley A. Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements. Nat. Biotechnol. 2018;36:765&#x2013;771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6390938</ArticleId><ArticleId IdType="pubmed">30010673</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaudelli N.M., Komor A.C., Rees H.A., Packer M.S., Badran A.H., Bryson D.I., Liu D.R. Programmable base editing of A&#x2022;T to G&#x2022;C in genomic DNA without DNA cleavage. Nature. 2017;551:464&#x2013;471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5726555</ArticleId><ArticleId IdType="pubmed">29160308</ArticleId></ArticleIdList></Reference><Reference><Citation>Komor A.C., Kim Y.B., Packer M.S., Zuris J.A., Liu D.R. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016;533:420&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4873371</ArticleId><ArticleId IdType="pubmed">27096365</ArticleId></ArticleIdList></Reference><Reference><Citation>Komor A.C., Badran A.H., Liu D.R. Editing the Genome Without Double-Stranded DNA Breaks. ACS Chem. Biol. 2018;13:383&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5891729</ArticleId><ArticleId IdType="pubmed">28957631</ArticleId></ArticleIdList></Reference><Reference><Citation>Rees H.A., Liu D.R. Base editing: precision chemistry on the genome and transcriptome of living cells. Nat. Rev. Genet. 2018;19:770&#x2013;788.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6535181</ArticleId><ArticleId IdType="pubmed">30323312</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurt I.C., Zhou R., Iyer S., Garcia S.P., Miller B.R., Langner L.M., Gr&#xfc;newald J., Joung J.K. CRISPR C-to-G base editors for inducing targeted DNA transversions in human cells. Nat Biotechnol. 2020;39:41&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7854778</ArticleId><ArticleId IdType="pubmed">32690971</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh W.H., Chiang H., Rees H.A., Edge A.S.B., Liu D.R. In&#xa0;vivo base editing of post-mitotic sensory cells. Nat. Commun. 2018;9:2184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5988727</ArticleId><ArticleId IdType="pubmed">29872041</ArticleId></ArticleIdList></Reference><Reference><Citation>Anzalone A.V., Randolph P.B., Davis J.R., Sousa A.A., Koblan L.W., Levy J.M., Chen P.J., Wilson C., Newby G.A., Raguram A., Liu D.R. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576:149&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6907074</ArticleId><ArticleId IdType="pubmed">31634902</ArticleId></ArticleIdList></Reference><Reference><Citation>DiMatteo D., Callahan S., Kmiec E.B. Genetic conversion of an SMN2 gene to SMN1: a novel approach to the treatment of spinal muscular atrophy. Exp. Cell Res. 2008;314:878&#x2013;886.</Citation><ArticleIdList><ArticleId IdType="pubmed">18078930</ArticleId></ArticleIdList></Reference><Reference><Citation>Corti S., Nizzardo M., Simone C., Falcone M., Nardini M., Ronchi D., Donadoni C., Salani S., Riboldi G., Magri F., et al. Genetic correction of human induced pluripotent stem cells from patients with spinal muscular atrophy. Sci. Transl. Med. 2012;4:165ra162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4722730</ArticleId><ArticleId IdType="pubmed">23253609</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou M., Hu Z., Qiu L., Zhou T., Feng M., Hu Q., Zeng B., Li Z., Sun Q., Wu Y., et al. Seamless Genetic Conversion of SMN2 to SMN1 via CRISPR/Cpf1 and Single-Stranded Oligodeoxynucleotides in Spinal Muscular Atrophy Patient-Specific Induced Pluripotent Stem Cells. Hum. Gene Ther. 2018;29:1252&#x2013;1263.</Citation><ArticleIdList><ArticleId IdType="pubmed">29598153</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J.J., Lin X., Tang C., Lu Y.Q., Hu X., Zuo E., et al. Disruption of splicing-regulatory elements using CRISPR/Cas9 rescues spinal muscular atrophy in human iPSCs and mice. Natl. Sci. Rev. 2019;6:15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8446915</ArticleId><ArticleId IdType="pubmed">34691481</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin X., Chen H., Lu Y.Q., Hong S., Hu X., Gao Y., Lai L.L., Li J.J., Wang Z., Ying W., et al. Base editing-mediated splicing correction therapy for spinal muscular atrophy. Cell Res. 2020;30:548&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7264321</ArticleId><ArticleId IdType="pubmed">32210360</ArticleId></ArticleIdList></Reference><Reference><Citation>Yun Y., Ha Y. CRISPR/Cas9-Mediated Gene Correction to Understand ALS. Int. J. Mol. Sci. 2020;21:3801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7312396</ArticleId><ArticleId IdType="pubmed">32471232</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaj T., Ojala D.S., Ekman F.K., Byrne L.C., Limsirichai P., Schaffer D.V. In&#xa0;vivo genome editing improves motor function and extends survival in a mouse model of ALS. Sci. Adv. 2017;3:eaar3952.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5738228</ArticleId><ArticleId IdType="pubmed">29279867</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan W., Guo M., Yi L., Liu Y., Li Z., Ma Y., Zhang G., Liu Y., Bu H., Song X., Li C. The deletion of mutant SOD1 via CRISPR/Cas9/sgRNA prolongs survival in an amyotrophic lateral sclerosis mouse model. Gene Ther. 2020;27:157&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">31819203</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim C.K.W., Gapinske M., Brooks A.K., Woods W.S., Powell J.E., Zeballos C M.A., Winter J., Perez-Pinera P., Gaj T. Treatment of a Mouse Model of ALS by In&#xa0;Vivo Base Editing. Mol. Ther. 2020;28:1177&#x2013;1189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7132599</ArticleId><ArticleId IdType="pubmed">31991108</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim C.K.W., Gapinske M., Brooks A.K., Woods W.S., Powell J.E., Zeballos C.M., Winter J., Perez-Pinera P., Gaj T. Treatment of a Mouse Model of ALS by In&#xa0;Vivo Base Editing. Mol. Ther. 2020;28:1177&#x2013;1189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7132599</ArticleId><ArticleId IdType="pubmed">31991108</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen P.M., Nordstr&#xf6;m U., Tsiakas K., Johannsen J., Volk A.E., Bierhals T., Zetterstr&#xf6;m P., Marklund S.L., Hempel M., Santer R. Phenotype in an Infant with SOD1 Homozygous Truncating Mutation. N.&#xa0;Engl. J. Med. 2019;381:486&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">31314961</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanden Broeck L., Callaerts P., Dermaut B. TDP-43-mediated neurodegeneration: towards a loss-of-function hypothesis? Trends Mol. Med. 2014;20:66&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">24355761</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E., Bercier V., Lissouba A., Liao M., Brustein E., Rouleau G.A., Drapeau P. FUS and TARDBP but not SOD1 interact in genetic models of amyotrophic lateral sclerosis. PLoS Genet. 2011;7:e1002214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3150442</ArticleId><ArticleId IdType="pubmed">21829392</ArticleId></ArticleIdList></Reference><Reference><Citation>Pribadi M., Yang Z., Kim T.S., Swartz E.W., Huang A.Y., Chen J.A., Dokuru D., Baek J., Gao F., Fua A.T., et al. Crispr-cas9 targeted deletion of the c9orf72 repeat expansion mutation corrects cellular phenotypes in patient-derived ips cells. bioRxiv. 2016 doi: 10.1101/051193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/051193</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvaraj B.T., Livesey M.R., Zhao C., Gregory J.M., James O.T., Cleary E.M., Chouhan A.K., Gane A.B., Perkins E.M., Dando O., et al. C9ORF72 repeat expansion causes vulnerability of motor neurons to Ca2+-permeable AMPA receptor-mediated excitotoxicity. Nat. Commun. 2018;9:347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5783946</ArticleId><ArticleId IdType="pubmed">29367641</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Gonzalez R., Yang D., Pribadi M., Kim T.S., Krishnan G., Choi S.Y., Lee S., Coppola G., Gao F.B. Partial inhibition of the overactivated Ku80-dependent DNA repair pathway rescues neurodegeneration in C9ORF72-ALS/FTD. Proc. Natl. Acad. Sci. USA. 2019;116:9628&#x2013;9633.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6511021</ArticleId><ArticleId IdType="pubmed">31019093</ArticleId></ArticleIdList></Reference><Reference><Citation>Ababneh N.A., Scaber J., Flynn R., Douglas A., Barbagallo P., Candalija A., Turner M.R., Sims D., Dafinca R., Cowley S.A., Talbot K. Correction of amyotrophic lateral sclerosis related phenotypes in induced pluripotent stem cell-derived motor neurons carrying a hexanucleotide expansion mutation in C9orf72 by CRISPR/Cas9 genome editing using homology-directed repair. Hum. Mol. Genet. 2020;29:2200&#x2013;2217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7399532</ArticleId><ArticleId IdType="pubmed">32504093</ArticleId></ArticleIdList></Reference><Reference><Citation>Abo-Rady M., Kalmbach N., Pal A., Schludi C., Janosch A., Richter T., Freitag P., Bickle M., Kahlert A.K., Petri S., et al. Knocking out C9ORF72 Exacerbates Axonal Trafficking Defects Associated with Hexanucleotide Repeat Expansion and Reduces Levels of Heat Shock Proteins. Stem Cell Reports. 2020;14:390&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7066330</ArticleId><ArticleId IdType="pubmed">32084385</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen B., Zhang W., Zhang J., Zhou J., Wang J., Chen L., Wang L., Hodgkins A., Iyer V., Huang X., Skarnes W.C. Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects. Nat. Methods. 2014;11:399&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">24584192</ArticleId></ArticleIdList></Reference><Reference><Citation>Meijboom K.E., Abdallah A., Fordham N., Hiroko Nagase H., Edraki A., Sontheimer E., et al. CRISPR/Cas9-Mediated Excision of ALS Causing Hexanucleotide Repeat Expansion in C9ORF72. ASGCT Annual Meeting 933. 2020;Abstract 966</Citation></Reference><Reference><Citation>Jeong Y.K., Song B., Bae S. Current Status and Challenges of DNA Base Editing Tools. Mol. Ther. 2020;28:1938&#x2013;1952.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7474268</ArticleId><ArticleId IdType="pubmed">32763143</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Li L., Ma Y., Hu H., Li Q., Yang Y., Liu W., Yin S., Li W., Fu B., et al. Reactivation of &#x3b3;-globin expression through Cas9 or base editor to treat &#x3b2;-hemoglobinopathies. Cell Res. 2020;30:276&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7054297</ArticleId><ArticleId IdType="pubmed">31911671</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Z., Wang S., Zhang C., Gao N., Li M., Wang D., Wang D., Liu D., Liu H., Ong S.G., et al. A compact Cas9 ortholog from Staphylococcus Auricularis (SauriCas9) expands the DNA targeting scope. PLoS Biol. 2020;18:e3000686.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7145270</ArticleId><ArticleId IdType="pubmed">32226015</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlesworth C.T., Deshpande P.S., Dever D.P., Camarena J., Lemgart V.T., Cromer M.K., Vakulskas C.A., Collingwood M.A., Zhang L., Bode N.M., et al. Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat. Med. 2019;25:249&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7199589</ArticleId><ArticleId IdType="pubmed">30692695</ArticleId></ArticleIdList></Reference><Reference><Citation>Louis Jeune V., Joergensen J.A., Hajjar R.J., Weber T. Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy. Hum. Gene Ther. Methods. 2013;24:59&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3732124</ArticleId><ArticleId IdType="pubmed">23442094</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G., Abdeen A.A., Wang Y., Shahi P.K., Robertson S., Xie R., Suzuki M., Pattnaik B.R., Saha K., Gong S. A biodegradable nanocapsule delivers a Cas9 ribonucleoprotein complex for in&#xa0;vivo genome editing. Nat. Nanotechnol. 2019;14:974&#x2013;980.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6778035</ArticleId><ArticleId IdType="pubmed">31501532</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>